Nature Communications (Sep 2016)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway

  • Mélissa Carbonneau,
  • Laurence M. Gagné,
  • Marie-Eve Lalonde,
  • Marie-Anne Germain,
  • Alena Motorina,
  • Marie-Christine Guiot,
  • Blandine Secco,
  • Emma E. Vincent,
  • Anthony Tumber,
  • Laura Hulea,
  • Jonathan Bergeman,
  • Udo Oppermann,
  • Russell G. Jones,
  • Mathieu Laplante,
  • Ivan Topisirovic,
  • Kevin Petrecca,
  • Marc-Étienne Huot,
  • Frédérick A. Mallette

DOI
https://doi.org/10.1038/ncomms12700
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 12

Abstract

Read online

Oncogenic mutations of isocitrate dehydrogenases 1 and 2 result in the production of the oncometabolite R-2-hydroxyglutarate. Here the authors show that the oncometabolite promotes mTOR activation in a PTEN/PI3K-independent manner by regulating DEPTOR stability via inhibition of KDM4A activity.